ZURICH (dpa-AFX Broker) - The major Swiss bank UBS has upgraded Carl Zeiss Meditec from "Neutral" to "Buy" and raised its target price from 89 to 125 euros. The shares of the medical technology group offer one of the best growth stories in the sector and are trading at only half the premium to the sector as in the past, analyst Graham Doyle wrote in a study published on Monday. The acquisition of ophthalmology specialist Dorc also offers more earnings potential (EPS) than the market has priced in, he added. He raised his estimates for adjusted EPS in the years up to 2028 by up to 17 percent./gl/ajx

Publication of the original study: 05.01.2024 / 18:44 / GMT First distribution of the original study: 05.01.2024 / 18:44 / GMT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------